|
Quotes & Info
|
| GTXI > SEC Filings for GTXI > Form 8-K on 17-Dec-2012 | All Recent SEC Filings |
17-Dec-2012
Other Events, Financial Statements and Exhibits
On December 17, 2012, GTx, Inc. issued a press release announcing that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer patients, a copy of which is furnished as Exhibit 99.1 to this Current Report.
(d) Exhibits
Exhibit
Number Description
99.1 Press Release issued by GTx, Inc. dated December 17, 2012
|
|
|